The age of enlightenment in melanoma immunotherapy

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

(2018) Margaret K. Callahan et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites

(2018) Zachary S. Morris et al.   Cancer Immunology Research

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

(2018) Ryan J. Sullivan et al.   Journal for ImmunoTherapy of Cancer

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapy for metastatic melanoma: an overview and update

(2011) Glen M Boyle   Expert Review of Anticancer Therapy

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

(2008) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY